Aging does not impact drug-drug interaction magnitudes with antiretrovirals: a Swiss HIV Cohort Study

The risk of drug-drug interactions (DDIs) is elevated in aging people living with HIV (PLWH) due to highly prevalent age-related comorbidities leading to more comedications. To investigate the impact of aging on DDI magnitudes between comedications (amlodipine, atorvastatin, rosuvastatin) and boosted darunavir, we conducted a clinical trial in aging PLWH >/=55 years. DDI magnitudes were comparable to those reported in young individuals supporting that the clinical management of DDIs in aging PLWH can be similar.